Abstract mRNA-based vaccines and therapeutic agents hold great promise in prevention
and treatment of human diseases, yet high percentage of systemic adverse effect in clinic …

Carrier-free naked mRNA vaccines may reduce the reactogenicity associated with delivery
carriers; however, their effectiveness against infectious diseases has been suboptimal. To …

Although inoculation of COVID-19 vaccines has rolled out globally, there is still a critical
need for safe and effective vaccines to ensure fair and equitable supply for all countries …

Advanced mRNA vaccines play vital roles against SARS-CoV-2. However, most current
mRNA delivery platforms need to be stored at− 20° C or− 70° C due to their poor stability …

SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high
transmissibility of the virus and the high rate of morbidity and mortality associated with …

In 2020, two mRNA-based vaccines, encoding the full length of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) spike protein, have been introduced for control of …

RNA vaccines have demonstrated efficacy against SARS-CoV-2 in humans, and the
technology is being leveraged for rapid emergency response. In this report, we assessed …

The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) evolution has
resulted in many variants, contributing to the striking drop in vaccine efficacy and …

A mouse model of SARS-CoV-2 that can be developed in any molecular biology lab with
standard facilities will be valuable in evaluating drugs and vaccines. Here we present a …

mRNA and lipid nanoparticles have emerged as powerful systems for the preparation of
vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection …